

# Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol on Prognosis in Patients with Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial

Journal of the American College of Cardiology

51, 724-730

DOI: [10.1016/j.jacc.2007.10.038](https://doi.org/10.1016/j.jacc.2007.10.038)

Citation Report

#	ARTICLE	IF	CITATIONS
1	PLASMA THYROTROPHIN LEVELS IN THYROID DISEASE AND EFFECT OF TREATMENT. European Journal of Endocrinology, 1969, 62, 593-606.	1.9	14
2	Triglycerides and risk for coronary artery disease. Current Atherosclerosis Reports, 2008, 10, 386-390.	2.0	92
3	Lipid management: Considerations in acute coronary syndrome. Current Cardiology Reports, 2008, 10, 334-341.	1.3	0
4	The role of triglycerides in cardiovascular risk. Current Cardiology Reports, 2008, 10, 505-511.	1.3	25
5	Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy. American Journal of Cardiology, 2008, 101, S27-S35.	0.7	16
6	Effectiveness of Combined Statin Plus Omega-3 Fatty Acid Therapy for Mixed Dyslipidemia. American Journal of Cardiology, 2008, 102, 1040-1045.	0.7	62
7	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. American Journal of Cardiology, 2008, 102, 1K-34K.	0.7	371
8	A Null Mutation in Human <i>APOC3</i> Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection. Science, 2008, 322, 1702-1705.	6.0	588
9	Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins. Clinical Drug Investigation, 2008, 28, 625-634.	1.1	34
10	Apolipoprotein CIII. Circulation Research, 2008, 103, 1348-1350.	2.0	13
11	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes and Vascular Disease Research, 2008, 5, 319-335.	0.9	227
12	Fibrates and future PPAR $\alpha$ agonists in the treatment of cardiovascular disease. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 542-553.	3.3	141
13	Nutrition and Cardiovascular Disease. Lippincott S Bone and Joint Newsletter, 2008, 34, 1-4.	0.0	0
14	Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting. Journal of Managed Care Pharmacy, 2008, 14, 1-31.	2.2	66
15	Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vascular Health and Risk Management, 2008, Volume 4, 991-1000.	1.0	53
16	Lipid-Modifying and Antiatherosclerotic Drugs. , 2009, , 341-372.		2
17	Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. Vascular Health and Risk Management, 2009, 5, 793.	1.0	38
18	JUPITER: major implications for vascular risk assessment. Current Medical Research and Opinion, 2009, 25, 133-137.	0.9	8

#	ARTICLE	IF	CITATIONS
19	Triglycerides and HDL Cholesterol. <i>Diabetes Care</i> , 2009, 32, S373-S377.	4.3	112
20	Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for Routine Clinical Use. <i>Circulation</i> , 2009, 119, 2396-2404.	1.6	77
21	Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009, 6, 98-100.	3.3	2
22	Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. <i>Stroke</i> , 2009, 40, 2486-2492.	1.0	66
23	An Emerging Paradigm in Atherosclerosis: Focus on Subclinical Disease. <i>Postgraduate Medicine</i> , 2009, 121, 49-59.	0.9	9
24	Omega-3 fatty acids for the treatment of elevated triglycerides. <i>Clinical Lipidology</i> , 2009, 4, 425-437.	0.4	17
25	Dyslipidemia and cardiovascular risk: the importance of early prevention. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2009, 102, 657-667.	0.2	108
26	Atherosclerosis and Physical Activity. <i>Oman Medical Journal</i> , 2009, 24, 173-8.	0.3	11
27	Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR <sup>-/-</sup> and apoE <sup>-/-</sup> mice. <i>Journal of Lipid Research</i> , 2009, 50, 1090-1100.	2.0	117
28	Discovery and Validation of New Molecular Targets in Treating Dyslipidemia: The Role of Human Genetics. <i>Trends in Cardiovascular Medicine</i> , 2009, 19, 195-201.	2.3	19
29	Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia. <i>Clinical Therapeutics</i> , 2009, 31, 862-879.	1.1	9
30	Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia. <i>American Journal of Cardiology</i> , 2009, 103, 515-522.	0.7	60
31	Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2009, 104, 459-463.	0.7	134
32	How Can We Improve the Management of Vascular Risk in Type 2 Diabetes: Insights from FIELD. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 403-408.	1.3	10
33	Should we treat all primary prevention patients with statins?. <i>Current Atherosclerosis Reports</i> , 2009, 11, 36-42.	2.0	1
34	Drug therapy for hypertriglyceridemia: Fibrates and omega-3 fatty acids. <i>Current Atherosclerosis Reports</i> , 2009, 11, 71-79.	2.0	32
35	Lipid management: Considerations in acute coronary syndrome. <i>Current Atherosclerosis Reports</i> , 2009, 11, 149-156.	2.0	1
36	Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease. <i>Current Atherosclerosis Reports</i> , 2009, 11, 281-288.	2.0	14

#	ARTICLE	IF	CITATIONS
37	Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis. <i>Cardiovascular Diabetology</i> , 2009, 8, 26.	2.7	23
38	Targeting triglycerides in secondary prevention: should we bother?. <i>International Journal of Clinical Practice</i> , 2009, 63, 15-18.	0.8	3
39	Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor- $\alpha$ . <i>British Journal of Pharmacology</i> , 2009, 158, 706-712.	2.7	33
40	Cholesterol Goals: Moving from Numbers to Treatment. <i>Clinical Cardiology</i> , 2009, 32, 106-108.	0.7	0
41	How to improve cardiovascular diseases prevention in Europe?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 451-454.	1.1	28
44	Beyond Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2009, 55, 35-41.	1.2	268
45	Efficacy and tolerability of multidrug therapy for hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2009, 3, 341-344.	0.6	2
46	Pediatric triglycerides predict cardiovascular disease events in the fourth to fifth decade of life. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1277-1284.	1.5	52
47	Dyslipidemia and Risk of Coronary Heart Disease: Role of Lifestyle Approaches for Its Management. <i>American Journal of Lifestyle Medicine</i> , 2009, 3, 257-273.	0.8	25
48	Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol. <i>Current Medical Research and Opinion</i> , 2009, 25, 1355-1363.	0.9	7
49	Association of plasma apolipoprotein AV with lipid profiles in patients with acute coronary syndrome. <i>Atherosclerosis</i> , 2009, 204, e99-e102.	0.4	20
50	Peroxisome proliferator-activated receptor-alpha (PPAR $\alpha$ ): At the crossroads of obesity, diabetes and cardiovascular disease. <i>Atherosclerosis</i> , 2009, 205, 1-8.	0.4	202
51	TriglicÃ©ridos en ayunas y posprandiales, y su contribuciÃ³n al estudio del riesgo cardiometabÃ³lico. <i>ClÃ¡nica E InvestigaciÃ³n En Arteriosclerosis</i> , 2009, 21, 290-297.	0.4	0
52	RÃªle de lâ€™entÃ©rocyte dans les anomalies lipidiques de lâ€™insulinorÃ©sistance. <i>Medecine Des Maladies Metaboliques</i> , 2009, 3, 567-574.	0.1	0
53	Triglycerides as vascular risk factors: new epidemiologic insights. <i>Current Opinion in Cardiology</i> , 2009, 24, 345-350.	0.8	129
55	Combination therapy of statins and fibrates in the management of cardiovascular risk. <i>Current Opinion in Lipidology</i> , 2009, 20, 505-511.	1.2	45
56	Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies. <i>Current Drug Targets</i> , 2009, 10, 320-327.	1.0	27
57	Fenofibric acid plus statin combination therapy for the treatment of mixed dyslipidemia. <i>Clinical Lipidology</i> , 2009, 4, 699-711.	0.4	1

#	ARTICLE	IF	CITATIONS
60	Extended-release niacin and laropirant in the management of dyslipidemias. <i>Clinical Lipidology</i> , 2010, 5, 783-791.	0.4	0
61	Comparative Study of Bezafibrate and Pravastatin in Patients With Coronary Artery Disease and High Levels of Remnant Lipoprotein. <i>Circulation Journal</i> , 2010, 74, 1644-1650.	0.7	20
62	Prognostic factors in patients who have survived myocardial infarction. <i>Open Medicine (Poland)</i> , 2010, 5, 513-519.	0.6	1
63	Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. , 2010, 126, 314-345.		196
64	Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control. <i>American Journal of Cardiology</i> , 2010, 106, 757-763.	0.7	124
65	Managing Mixed Dyslipidemia in Special Populations. <i>Preventive Cardiology</i> , 2010, 13, 78-83.	1.1	7
66	High-Dose Atorvastatin in Acute Coronary and Cerebrovascular Syndromes – Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 340-342.	1.1	11
67	Combined therapy in the treatment of dyslipidemia. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 19-28.	1.0	81
68	Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease. <i>Journal of Multidisciplinary Healthcare</i> , 2010, 3, 79.	1.1	7
69	INSIG1 influences obesity-related hypertriglyceridemia in humans. <i>Journal of Lipid Research</i> , 2010, 51, 701-708.	2.0	34
70	Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?. <i>Clinical Lipidology</i> , 2010, 5, 811-826.	0.4	23
71	Non-LDL-related dyslipidaemia and coronary risk: a case-control study. <i>Diabetes and Vascular Disease Research</i> , 2010, 7, 204-212.	0.9	21
72	Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. <i>European Heart Journal</i> , 2010, 31, 149-164.	1.0	256
73	Varespladib methyl in cardiovascular disease. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1245-1255.	1.9	18
74	The Metabolic Syndrome, Its Component Risk Factors, and Progression of Coronary Atherosclerosis. <i>Archives of Internal Medicine</i> , 2010, 170, 478.	4.3	114
75	<i>KIF6</i> Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 455-461.	3.1	65
76	To B or Not to B: Is Non-High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B?. <i>Mayo Clinic Proceedings</i> , 2010, 85, 446-450.	1.4	17
77	The lipid triad, or how to reduce residual cardiovascular risk?. <i>Annales D'Endocrinologie</i> , 2010, 71, 89-94.	0.6	7

#	ARTICLE	IF	CITATIONS
79	Insights from recent meta-analysis: Role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression. <i>Journal of Clinical Lipidology</i> , 2010, 4, 365-370.	0.6	14
80	Drug Treatment of Hyperlipidaemia. <i>Drugs</i> , 2010, 70, 1363-1379.	4.9	42
81	Treating Mixed Hyperlipidemia and the Atherogenic Lipid Phenotype for Prevention of Cardiovascular Events. <i>American Journal of Medicine</i> , 2010, 123, 892-898.	0.6	33
82	Dislipemia aterog�nica: una llamada de atenci�n sobre su papel en el riesgo residual. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2010, 22, 162-166.	0.4	0
83	Association between dyslipidemia and vascular events in patients treated with statins: Report from the UK General Practice Research Database. <i>Atherosclerosis</i> , 2010, 208, 210-216.	0.4	17
84	Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis. <i>Atherosclerosis</i> , 2010, 212, 9-15.	0.4	63
85	Fibrates in CVD: a step towards personalised medicine. <i>Lancet, The</i> , 2010, 375, 1847-1848.	6.3	10
86	Risque cardiovasculaire r�siduel du patient diab�tique de type 2. <i>Medecine Des Maladies Metaboliques</i> , 2010, 4, 389-393.	0.1	1
87	A review of simple, non-invasive means of assessing peripheral arterial disease and implications for medical management. <i>Annals of Medicine</i> , 2010, 42, 115-126.	1.5	46
88	Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R <sup>3</sup> ). <i>Current Medical Research and Opinion</i> , 2010, 26, 1793-1797.	0.9	46
89	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011, 32, 1345-1361.	1.0	993
90	Triglycerides and Cardiovascular Disease. <i>Circulation</i> , 2011, 123, 2292-2333.	1.6	1,511
91	The REALIST (REsiduAl risk, Lipids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome. <i>Endocrinolog�a Y Nutrici�n (English)</i> Tj ETQq0 0 0 rgBT / Overlock 16 Tf 50 257	0.6	10
92	Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease. <i>Endocrinolog�a Y Nutrici�n (English Edition)</i> , 2011, 58, 283-290.	0.5	2
93	Another Step Forward in Refining Risk Stratification. <i>Journal of the American College of Cardiology</i> , 2011, 58, 464-466.	1.2	6
96	Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. <i>Heart</i> , 2011, 97, 350-356.	1.2	87
97	Comprehensive Cardiovascular Medicine in the Primary Care Setting. , 2011, , .		0
98	Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy. <i>Current Medical Research and Opinion</i> , 2011, 27, 2165-2173.	0.9	15

#	ARTICLE	IF	CITATIONS
99	Riesgo residual vascular de origen lipídico. Estrategias para el tratamiento del riesgo residual por dislipidemia aterogénica. Clínica E Investigaci3n En Arteriosclerosis, 2011, 23, 230-239.	0.4	0
100	Associations of atherosclerotic risk factors with oxidized low-density lipoprotein evaluated by LOX-1 ligand activity in healthy men. Clinica Chimica Acta, 2011, 412, 1643-1647.	0.5	20
101	Lipids, lipid-lowering therapy and diabetes complications. Diabetes and Metabolism, 2011, 37, 15-24.	1.4	25
102	Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic. European Journal of Internal Medicine, 2011, 22, 412-417.	1.0	15
103	Republished review: Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Postgraduate Medical Journal, 2011, 87, 776-782.	0.9	8
104	Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis. Atherosclerosis, 2011, 217, 492-498.	0.4	206
105	Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment. Open Cardiovascular Medicine Journal, 2011, 5, 24-34.	0.6	55
106	Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin. Clinical Medicine Insights Therapeutics, 2011, 3, CMT.S6565.	0.4	0
107	Residual Vascular Risk in T2DM: The Next Frontier. , 2011, , .		2
108	Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Design, Development and Therapy, 2011, 5, 325.	2.0	201
109	Clinical predictors for progression of nonintervened nonculprit coronary lesions despite low-density lipoprotein cholesterol less than 1.8 mmol/l after successful stent implantation. Coronary Artery Disease, 2011, 22, 49-54.	0.3	5
110	Anacetrapib: A New Weapon Against Dyslipidemia. Current Clinical Pharmacology, 2011, 6, 227-235.	0.2	1
111	Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 Inhibition and Thrombin Receptor Antagonists. Current Drug Targets, 2011, 12, 1805-1812.	1.0	4
112	Lipid Profile Changes During the First Year After Kidney Transplantation: Risk Factors and Influence of the Immunosuppressive Drug Regimen. Transplantation Proceedings, 2011, 43, 3730-3737.	0.3	52
113	Fixed-Dose Combination Fenofibrate/Pravastatin 160/40 mg Versus Simvastatin 20 mg Monotherapy in Adults With Type 2 Diabetes and Mixed Hyperlipidemia Uncontrolled With Simvastatin 20 mg: A Double-Blind, Randomized Comparative Study. Clinical Therapeutics, 2011, 33, 1-12.	1.1	33
114	Impact of Hypertriglyceridemia on Endothelial Dysfunction During Statin ± Ezetimibe Therapy in Patients With Coronary Heart Disease. American Journal of Cardiology, 2011, 108, 333-339.	0.7	32
115	Residual cardiovascular risk in secondary prevention. Internal and Emergency Medicine, 2011, 6, 61-68.	1.0	6
116	Blood Lipids and Stroke: What More Can We Do Besides Reducing Low-Density Lipoprotein Cholesterol?. Current Atherosclerosis Reports, 2011, 13, 306-313.	2.0	3

#	ARTICLE	IF	CITATIONS
117	The Role of Triglycerides in Atherosclerosis. <i>Current Cardiology Reports</i> , 2011, 13, 544-552.	1.3	260
118	Hypertriglyceridaemia in statin-treated type 2 diabetic patients. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2011, 28, 257-260.	0.2	2
120	Safety review of combination drugs for hyperlipidemia. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 363-371.	1.0	16
121	Combination lipid therapy in type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1393-1403.	0.9	4
122	The ezetimibe controversy: implications for clinical practice. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2011, 5, 199-208.	1.0	14
123	LDL-C or apoB as the best target for reducing coronary heart disease: should apoB be implemented into clinical practice?. <i>Clinical Lipidology</i> , 2011, 6, 35-48.	0.4	3
124	High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome. <i>Pharmacogenomics Journal</i> , 2011, 11, 162-173.	0.9	8
125	Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 987-997.	0.6	6
126	Abdominal obesity modifies the risk of hypertriglyceridemia for all-cause and cardiovascular mortality in hemodialysis patients. <i>Kidney International</i> , 2011, 79, 765-772.	2.6	39
127	Lipid parameters for measuring risk of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2011, 8, 197-206.	6.1	177
128	Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 203-233.	1.0	1
129	Pitavastatin: finding its place in therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2011, 2, 101-117.	1.1	13
131	Associations of Polymorphisms in the Apolipoprotein APOA1-C3-A5 Gene Cluster with Acute Coronary Syndrome. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-5.	3.0	28
132	LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. <i>Journal of Lipid Research</i> , 2012, 53, 556-560.	2.0	11
133	Novel Strategies for Managing Dyslipidemia: Treatment beyond Statins. <i>Postgraduate Medicine</i> , 2012, 124, 43-54.	0.9	13
134	Puesta al día en el manejo de las dislipidemias. <i>Revista Médica Clínica Las Condes</i> , 2012, 23, 681-687.	0.2	1
135	Pediatric Metabolic Syndrome. , 2012, , .		8
136	Dislipidemia diabética, macro y microangiopatía. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2012, 24, 299-305.	0.4	3



#	ARTICLE	IF	CITATIONS
137	Hospital use and medical care costs up to 5 years after triglyceride lowering among patients with severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2012, 6, 443-449.	0.6	8
138	Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidence. <i>Journal of Clinical Lipidology</i> , 2012, 6, 413-426.	0.6	74
139	Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2012, 6, 450-461.	0.6	54
141	Triglycerides: How Much Credit Do They Deserve?. <i>Medical Clinics of North America</i> , 2012, 96, 39-55.	1.1	16
142	Combined extractives of red yeast rice, bitter melon, chlorella, soy protein, and licorice improve total cholesterol, low-density lipoprotein cholesterol, and triglyceride in subjects with metabolic syndrome. <i>Nutrition Research</i> , 2012, 32, 85-92.	1.3	31
143	Caveats to aggressive lowering of lipids by specific statins. <i>International Journal of Cardiology</i> , 2012, 154, 97-101.	0.8	21
144	The characteristics of remnant lipoproteins in the fasting and postprandial plasma. <i>Clinica Chimica Acta</i> , 2012, 413, 1077-1086.	0.5	33
145	Pharmacological Therapies of Metabolic Syndrome. , 2012, , 311-332.		0
146	Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality. <i>Current Cardiology Reports</i> , 2012, 14, 709-720.	1.3	93
147	Omega-3 in Antiarrhythmic Therapy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2012, 19, 201-205.	1.0	3
148	Peroxisome Proliferator-Activated Receptor $\alpha$ (PPAR $\alpha$ ) as a Potential Therapeutic Target for Dyslipidemia. , 2012, , .		0
149	Targeting PPAR $\alpha$ for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 209-223.	1.5	36
150	A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 906-921.	1.5	105
151	Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. <i>Current Atherosclerosis Reports</i> , 2012, 14, 1-10.	2.0	304
152	Do Persons with Diabetes Benefit from Combination Statin and Fibrate Therapy?. <i>Current Cardiology Reports</i> , 2012, 14, 112-124.	1.3	20
153	How to control residual cardiovascular risk despite statin treatment: Focusing on HDL cholesterol. <i>International Journal of Cardiology</i> , 2013, 166, 8-14.	0.8	54
154	Plasma triglyceride levels increase the risk for recurrent vascular events independent of LDL-cholesterol or nonHDL-cholesterol. <i>International Journal of Cardiology</i> , 2013, 167, 403-408.	0.8	23
155	Joint Linkage and Association Analysis with Exome Sequence Data Implicates SLC25A40 in Hypertriglyceridemia. <i>American Journal of Human Genetics</i> , 2013, 93, 1035-1045.	2.6	36

#	ARTICLE	IF	CITATIONS
156	The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome. <i>Lipids in Health and Disease</i> , 2013, 12, 133.	1.2	9
157	Demystifying the management of hypertriglyceridaemia. <i>Nature Reviews Cardiology</i> , 2013, 10, 648-661.	6.1	92
158	Role of enterocytes in dyslipidemia of insulin-resistant states. <i>Endocrinología Y Nutrición (English)</i> Tj ETQq0 0 0 rgBT /Overlck 10 Tf 5	0.5	1
159	Extended-release niacin/laropiprant for lipid management: observational study in clinical practice. <i>International Journal of Clinical Practice</i> , 2013, 67, 527-535.	0.8	2
160	PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1567-1577.	0.6	14
161	Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized long-term (ORL) study. <i>Journal of Clinical Lipidology</i> , 2013, 7, 615-625.	0.6	26
162	Rol del enterocito en la dislipemia de la resistencia insulínica. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2013, 60, 179-189.	0.8	2
163	Statin Treatment Improves Plasma Lipid Levels but not HDL Subclass Distribution in Patients Undergoing Percutaneous Coronary Intervention. <i>Lipids</i> , 2013, 48, 127-137.	0.7	6
164	What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 104-117.	0.4	6
165	Comparative cardiometabolic effects of fibrates and omega-3 fatty acids. <i>International Journal of Cardiology</i> , 2013, 167, 2404-2411.	0.8	7
166	Epanova <sup>®</sup> and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy. <i>Future Cardiology</i> , 2013, 9, 177-186.	0.5	12
167	Reducing residual risk: modern pharmacology meets old-fashioned lifestyle and adherence improvement. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2013, 7, 169-182.	1.0	3
168	Atherogenic dyslipidemia. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 969.	0.2	62
169	Mortality risk of triglyceride levels in patients with coronary artery disease. <i>Heart</i> , 2013, 99, 22-29.	1.2	40
170	Therapy to Manage Low High-Density Lipoprotein Cholesterol and Elevated Triglycerides. , 2013, , 434-441.		0
171	Triglycerides and cardiovascular risk. <i>Heart</i> , 2013, 99, 1-2.	1.2	15
172	Genetically elevated levels of circulating triglycerides and brachial ankle pulse wave velocity in a Chinese population. <i>Journal of Human Hypertension</i> , 2013, 27, 265-270.	1.0	18
173	Optimal use of lipid-altering therapy: guidelines versus evidence. <i>Clinical Lipidology</i> , 2013, 8, 269-272.	0.4	0

#	ARTICLE	IF	CITATIONS
174	Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. <i>Vascular Health and Risk Management</i> , 2013, 9, 617.	1.0	71
175	Contemporary Management and Attainment of Cholesterol Targets for Patients with Dyslipidemia in China. <i>PLoS ONE</i> , 2013, 8, e47681.	1.1	22
176	Emergent Biomarkers of Residual Cardiovascular Risk in Patients with Low HDL-c and/or High Triglycerides and Average LDL-c Concentrations: Focus on HDL Subpopulations, Oxidized LDL, Adiponectin, and Uric Acid. <i>Scientific World Journal</i> , The, 2013, 2013, 1-16.	0.8	7
177	Rs964184 (APOA5-A4-C3-A1) Is Related to Elevated Plasma Triglyceride Levels, but Not to an Increased Risk for Vascular Events in Patients with Clinically Manifest Vascular Disease. <i>PLoS ONE</i> , 2014, 9, e101082.	1.1	22
178	Risk prediction with triglycerides in patients with stable coronary disease on statin treatment. <i>Clinical Research in Cardiology</i> , 2014, 103, 984-997.	1.5	10
179	Effect of Atorvastatin on Low-Density Lipoprotein Subpopulations and Comparison Between Indicators of Plasma Atherogenicity. <i>Angiology</i> , 2014, 65, 794-799.	0.8	16
180	Evolving targets for lipid-modifying therapy. <i>EMBO Molecular Medicine</i> , 2014, 6, 1215-1230.	3.3	11
181	Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 519-526.	2.2	11
182	Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families. <i>Clinical Genetics</i> , 2014, 85, 433-440.	1.0	19
183	Differences in Lipid Profiles in Two Hispanic Ischemic Stroke Populations. <i>International Journal of Stroke</i> , 2014, 9, 394-399.	2.9	5
184	Improving heart function by modulating myocardiocyte autophagy: a possible novel mechanism for cardiovascular protection of high-density lipoprotein. <i>Lipids in Health and Disease</i> , 2014, 13, 163.	1.2	9
185	Postprandial hypertriglyceridemia as a coronary risk factor. <i>Clinica Chimica Acta</i> , 2014, 431, 131-142.	0.5	157
186	Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: Effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size. <i>Journal of Cardiology</i> , 2014, 63, 60-68.	0.8	26
187	Triglyceride-to-HDL cholesterol ratio. <i>Herz</i> , 2014, 39, 105-110.	0.4	31
188	Update in Therapeutic Approaches to Plaque Stabilization. <i>Current Atherosclerosis Reports</i> , 2014, 16, 392.	2.0	4
189	Endothelial Dysfunction and Dyslipidemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy. <i>Contemporary Diabetes</i> , 2014, , 239-278.	0.0	0
190	Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients. <i>Contemporary Diabetes</i> , 2014, , 373-398.	0.0	0
191	Prise en charge du diab�tque apr�s infarctus du myocarde. , 2014, , 353-358.		0

#	ARTICLE	IF	CITATIONS
192	Dislipemia aterÃ³gena: una entidad que no debe pasar inadvertida. Revista Clinica Espanola, 2014, 214, 513-514.	0.2	0
193	Effects of Bariatric Surgery on Hepatic and Intestinal Lipoprotein Particle Metabolism in Obese, Nondiabetic Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2330-2337.	1.1	41
194	Lipid pharmacotherapy for treatment of atherosclerosis. Expert Opinion on Pharmacotherapy, 2014, 15, 1119-1125.	0.9	13
195	Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides. Atherosclerosis, 2014, 236, 244-250.	0.4	42
196	Clinical Strategies for Managing Dyslipidemias. American Journal of Lifestyle Medicine, 2014, 8, 216-230.	0.8	1
197	Lipoproteins as Biomarkers and Therapeutic Targets in the Setting of Acute Coronary Syndrome. Circulation Research, 2014, 114, 1880-1889.	2.0	38
198	Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke, 2014, 45, 2160-2236.	1.0	3,891
199	Impact of admission triglyceride for early outcome in diabetic patients with stable coronary artery disease. Lipids in Health and Disease, 2014, 13, 73.	1.2	9
200	The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!. Current Medical Research and Opinion, 2014, 30, 1701-1705.	0.9	9
201	2014 Meet-The-Professor: Endocrine Case Management. , 2014, , .		0
202	High Remnant Lipoprotein Predicts Recurrent Cardiovascular Events on Statin Treatment After Acute Coronary Syndrome. Circulation Journal, 2014, 78, 2492-2500.	0.7	25
203	Krill oil reduces plasma triacylglycerol level and improves related lipoprotein particle concentration, fatty acid composition and redox status in healthy young adults - a pilot study. Lipids in Health and Disease, 2015, 14, 163.	1.2	35
204	The Effects of Allopurinol on the Carotid Intima-media Thickness in Patients with Type 2 Diabetes and Asymptomatic Hyperuricemia: A Three-year Randomized Parallel-controlled Study. Internal Medicine, 2015, 54, 2129-2137.	0.3	55
205	Single and mixed dyslipidaemia in Canadian primary care settings: findings from the Canadian primary care sentinel surveillance network database. BMJ Open, 2015, 5, e007954.	0.8	13
206	Effects of Docosahexaenoic Acid on the Endothelial Function in Patients with Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2015, 22, 447-454.	0.9	29
207	Triglyceride-Rich Lipoproteins and Coronary Artery Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, e3-9.	1.1	61
208	Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins. Journal of the American College of Cardiology, 2015, 65, 2267-2275.	1.2	210
209	The Remnants of Residual Riskâ—. Journal of the American College of Cardiology, 2015, 65, 2276-2278.	1.2	19

#	ARTICLE	IF	CITATIONS
210	Hydrogen sulfide reduces serum triglyceride by activating liver autophagy via the AMPK-mTOR pathway. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 309, E925-E935.	1.8	107
211	The past, present and future of lipid-lowering therapy. <i>Clinical Lipidology</i> , 2015, 10, 481-498.	0.4	6
212	Serum Triglyceride Levels and Cardiovascular Disease Events in Koreans. <i>Cardiology</i> , 2015, 131, 228-235.	0.6	23
213	Optimal Carbohydrate and Nutrient Intake for Japanese Elderly Patients with Type 2 Diabetes. , 2015, , 315-325.		0
214	Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature. <i>Atherosclerosis</i> , 2015, 242, 647-656.	0.4	56
215	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statins and Newer Drugs. <i>Drugs</i> , 2015, 75, 1201-1228.	4.9	18
216	The association of dyslipidemia with erythrocyte aggregation. <i>Clinical Lipidology</i> , 2015, 10, 129-135.	0.4	6
217	The role of apoB measurement in Type 2 diabetic patients. <i>Clinical Lipidology</i> , 2015, 10, 137-144.	0.4	2
218	Looking to the horizon: the role of bilirubin in the development and prevention of age-related chronic diseases. <i>Clinical Science</i> , 2015, 129, 1-25.	1.8	126
219	Î±-Lipoic acid as a triglyceride-lowering nutraceutical. <i>Canadian Journal of Physiology and Pharmacology</i> , 2015, 93, 1029-1041.	0.7	23
220	Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. <i>Cardiology Clinics</i> , 2015, 33, 299-308.	0.9	3
221	Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease. <i>Cardiology Clinics</i> , 2015, 33, 309-323.	0.9	15
222	Therapy and clinical trials. <i>Current Opinion in Lipidology</i> , 2015, 26, 70-71.	1.2	0
223	Elevated Triglycerides, Atherosclerosis and Adverse Clinical Events. , 2015, , 55-67.		0
224	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate+statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015, 19, 1-12.	1.2	66
225	Controversies in Cardiology. , 2015, , .		0
226	Impact of Lipoprotein(a) as Residual Risk on Long-Term Outcomes in Patients After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2015, 115, 157-160.	0.7	38
227	Ongoing challenges for pharmacotherapy for dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 347-356.	0.9	6

#	ARTICLE	IF	CITATIONS
228	Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors. <i>Current Medical Research and Opinion</i> , 2015, 31, 435-438.	0.9	4
229	Influence of Atorvastatin on Plasma Atherogenic Biomarkers. , 0, , .		1
230	Factors associated with lipid goal attainment among acute coronary syndrome patients. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 1631-1637.	0.8	2
232	Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 282-303.	0.7	13
233	Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia. <i>Cardiology</i> , 2016, 135, 3-12.	0.6	11
234	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. <i>Vascular Health and Risk Management</i> , 2016, 12, 171.	1.0	166
235	Lipids in Coronary Heart Disease. , 2016, , 67-80.		0
236	Hypertriglyceridemia and Cardiovascular Outcomes. <i>American Journal of Therapeutics</i> , 2016, 23, e862-e870.	0.5	6
237	Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk. <i>Current Cardiology Reports</i> , 2016, 18, 65.	1.3	13
238	Pitavastatin versus Pravastatin in Reduction of Remnant Lipoprotein Cholesterol in Patients with Dyslipidemias. <i>Clinical Therapeutics</i> , 2016, 38, 1250-1251.	1.1	1
239	A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. <i>American Journal of Cardiology</i> , 2016, 117, 1444-1448.	0.7	78
240	Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 206-212.	0.9	71
242	The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. <i>Lipids in Health and Disease</i> , 2016, 15, 118.	1.2	131
243	Hypertriglyceridemia: the importance of identifying patients at risk. <i>Postgraduate Medicine</i> , 2016, 128, 848-858.	0.9	28
244	Efectos de la suplementaci3n con testosterona sobre el rendimiento en resistencia. <i>Revista Andaluza De Medicina Del Deporte</i> , 2016, 9, 131-137.	0.1	2
245	Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment. <i>International Journal of Cardiology</i> , 2016, 221, 832-836.	0.8	15
246	Targeting ApoC-III to Reduce Coronary Disease Risk. <i>Current Atherosclerosis Reports</i> , 2016, 18, 54.	2.0	31
247	Comparative analysis of the efficacy of omega-3 fatty acids for hypertriglyceridaemia management in Korea. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 508-514.	0.7	1

#	ARTICLE	IF	CITATIONS
249	Olive oil and postprandial hyperlipidemia: implications for atherosclerosis and metabolic syndrome. <i>Food and Function</i> , 2016, 7, 4734-4744.	2.1	26
251	Optimal cutoff of the triglyceride to high-density lipoprotein cholesterol ratio to detect cardiovascular risk factors among Han adults in Xinjiang. <i>Journal of Health, Population and Nutrition</i> , 2016, 35, 30.	0.7	19
252	Apoprotein C-III: A review of its clinical implications. <i>Clinica Chimica Acta</i> , 2016, 460, 50-54.	0.5	18
253	Where to now in cardiovascular disease prevention. <i>Atherosclerosis</i> , 2016, 251, 483-489.	0.4	2
254	Triglycerides are a predictive factor for arterial stiffness: a community-based 4.8-year prospective study. <i>Lipids in Health and Disease</i> , 2016, 15, 97.	1.2	36
255	A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. <i>Hospital Practice (1995)</i> , 2016, 44, 9-20.	0.5	1
256	Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 171-184.	1.2	1
257	Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 185-204.	1.2	20
258	Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease. <i>Circulation Research</i> , 2016, 118, 547-563.	2.0	701
260	Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1895-1900.	3.3	16
261	Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia. <i>Clinical Therapeutics</i> , 2016, 38, 603-609.	1.1	12
262	Slippery Slope of Triglycerides. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 97-99.	0.9	4
263	Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease. <i>Clinical Chemistry</i> , 2016, 62, 593-604.	1.5	138
264	Fasting or Nonfasting Lipid Measurements. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1227-1234.	1.2	63
265	Association of lecithin-cholesterol acyltransferase activity measured as a serum cholesterol esterification rate and low-density lipoprotein heterogeneity with cardiovascular risk: a cross-sectional study. <i>Heart and Vessels</i> , 2016, 31, 831-840.	0.5	15
266	Predictive value of non-fasting remnant cholesterol for short-term outcome of diabetics with new-onset stable coronary artery disease. <i>Lipids in Health and Disease</i> , 2017, 16, 7.	1.2	22
267	Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2017, 19, 19.	1.3	19
268	2017 Taiwan lipid guidelines for high risk patients. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 217-248.	0.8	123



#	ARTICLE	IF	CITATIONS
269	Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients. <i>Aids</i> , 2017, 31, 965-971.	1.0	4
270	Effect of <i>Gymnema sylvestris</i> Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion. <i>Journal of Medicinal Food</i> , 2017, 20, 750-754.	0.8	26
271	Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 447-452.	1.0	2
272	Triglycerides Revisited to the Serial. <i>Advances in Clinical Chemistry</i> , 2017, 80, 1-44.	1.8	7
273	Current status of lipid management in acute coronary syndrome. <i>Journal of Cardiology</i> , 2017, 70, 101-106.	0.8	16
274	Triglycerides: A reappraisal. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 428-432.	2.3	12
275	Hypertriglyceridaemia and risk of coronary artery disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 401-411.	6.1	257
276	A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. <i>Advances in Therapy</i> , 2017, 34, 300-323.	1.3	37
277	Triglyceride-lowering trials. <i>Current Opinion in Lipidology</i> , 2017, 28, 477-487.	1.2	12
278	Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?. <i>Postgraduate Medicine</i> , 2017, 129, 822-827.	0.9	22
279	Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner. <i>Pharmacogenomics Journal</i> , 2017, 17, 222-229.	0.9	14
280	Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2017, 119, 410-415.	0.7	8
281	Managing hypertriglyceridemia. <i>Nurse Practitioner</i> , 2017, 42, 3-9.	0.2	1
282	Clinical Assessment of Brachial-Ankle Pulse Wave Velocity and Stiffness Index: Hypertriglyceridemia Effects on Arterial Stiffness. , 2017, , .		0
283	Homogeneous Assays for LDL-C and HDL-C are Reliable in Both the Postprandial and Fasting State. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 583-599.	0.9	39
284	Apolipoprotein A-I exchange is impaired in metabolic syndrome patients asymptomatic for diabetes and cardiovascular disease. <i>PLoS ONE</i> , 2017, 12, e0182217.	1.1	22
285	Lipid Lowering Therapy to Modify Plaque Microstructures:. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 360-372.	0.9	7
286	Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. <i>Clinical Cardiology</i> , 2018, 41, 13-19.	0.7	63



#	ARTICLE	IF	CITATIONS
287	Relaci3n triglic3ridos/colesterol de la lipoprote3na de alta densidad como indicador de riesgo cardiometab3lico en ni3os y adolescentes de la ciudad de M3rida, Venezuela. <i>Endocrinologia, Diabetes Y Nutrici3n</i> , 2018, 65, 74-83.	0.1	4
288	Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 197-205.	1.1	34
289	The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT3TIMI 22. <i>Clinical Cardiology</i> , 2018, 41, 68-73.	0.7	5
290	A novel and simply calculated nutritional index serves as a useful prognostic indicator in patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2018, 262, 92-98.	0.8	31
291	Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. <i>Korean Circulation Journal</i> , 2018, 48, 1097.	0.7	15
292	Association of Serum Triglycerides With Arterial Stiffness in Subjects With Low Levels of Low-Density Lipoprotein Cholesterol. <i>Circulation Journal</i> , 2018, 82, 3052-3057.	0.7	7
293	Beyond Statins: Who and When to Prescribe?. <i>Current Diabetes Reports</i> , 2018, 18, 126.	1.7	4
294	High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk. <i>Journal of the American Heart Association</i> , 2018, 7, e008740.	1.6	81
295	Serum triglycerides predict first cardiovascular events in diabetic patients with hypercholesterolemia and retinopathy. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1852-1860.	0.8	21
296	Triglycerides/High density lipoprotein cholesterol ratio as a cardiometabolic risk marker in children and adolescents from M3rida city, Venezuela. <i>Endocrinolog3a Diabetes Y Nutrici3n (English Ed )</i> , 2018, 65, 74-83.	0.1	3
297	Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care. <i>Journal of the Endocrine Society</i> , 2018, 2, 497-512.	0.1	19
298	Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 244-256.	2.3	14
299	On-treatment lipid profiles to predict the cardiovascular outcomes in ASCVD patients comorbid with chronic kidney disease 3 The multi-center T-SPARCLE registry study. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 814-824.	0.8	9
300	Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. <i>Journal of the American College of Cardiology</i> , 2018, 72, 330-343.	1.2	152
301	Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 237-242.	1.4	6
302	A study on the relationship between waist phenotype, hypertriglyceridemia, coronary artery lesions and serum free fatty acids in adult and elderly patients with coronary diseases. <i>Immunity and Ageing</i> , 2018, 15, 14.	1.8	9
303	Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3019-3027.	1.8	74
304	Cardiovascular Risk Assessment in Patients with Hypertriglyceridemia. <i>Current Cardiology Reports</i> , 2018, 20, 71.	1.3	0

#	ARTICLE	IF	CITATIONS
305	Comparison of Medical Care Utilization and Costs Among Patients With Statin-Controlled Low-Density Lipoprotein Cholesterol With Versus Without Hypertriglyceridemia. <i>American Journal of Cardiology</i> , 2018, 122, 1128-1132.	0.7	10
306	The Effects of Long-Term Dietary Therapy on Patients with Hypertriglyceridemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 39-49.	0.9	6
307	Non-HDL as a Valid Surrogate Marker of Small Dense LDL in a Young Indian Population. <i>Indian Journal of Clinical Biochemistry</i> , 2019, 34, 263-271.	0.9	2
308	Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysis. <i>Clinical Cardiology</i> , 2019, 42, 908-913.	0.7	10
309	Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids. <i>Journal of Clinical Lipidology</i> , 2019, 13, 634-644.	0.6	32
310	TIMD4 rs6882076 SNP Is Associated with Decreased Levels of Triglycerides and the Risk of Coronary Heart Disease and Ischemic Stroke. <i>International Journal of Medical Sciences</i> , 2019, 16, 864-871.	1.1	9
311	Identification of Differential Roles of MicroRNA-33a and -33b During Atherosclerosis Progression With Genetically Modified Mice. <i>Journal of the American Heart Association</i> , 2019, 8, e012609.	1.6	17
312	Rounding the corner on residual risk: Implications of REDUCE-IT for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. <i>Clinical Cardiology</i> , 2019, 42, 829-838.	0.7	13
313	National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. <i>Journal of Clinical Lipidology</i> , 2019, 13, 860-872.	0.6	79
314	Implications for REDUCE IT in clinical practice. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 395-400.	1.6	12
315	Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1670-1680.	1.4	45
316	Ambient air pollution and lipid profile: Systematic review and meta-analysis. <i>Environmental Pollution</i> , 2019, 254, 113036.	3.7	67
317	Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes. <i>Circulation</i> , 2019, 140, 1308-1317.	1.6	172
318	Mitigating Risk Patients With Dyslipidemia. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1659-1661.	1.4	0
319	Targeting RNA to lower triglycerides: long strides from short molecules. <i>European Heart Journal</i> , 2019, 40, 2797-2800.	1.0	10
320	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	2.7	104
321	Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. <i>Lipids in Health and Disease</i> , 2019, 18, 134.	1.2	40
322	Atherogenic markers in predicting cardiovascular risk and targeting residual cardiovascular risk. <i>Atherosclerosis: X</i> , 2019, 1, 100001.	0.0	3

#	ARTICLE	IF	CITATIONS
323	Effects of Icosapent Ethyl on Total Ischemic Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2791-2802.	1.2	208
324	Current pharmacotherapeutic options for primary dyslipidemia in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1277-1288.	0.9	18
325	Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 75-88.	0.1	6
326	Long-Term Comparison of Ethyl Icosapentate vs. Omega-3-Acid Ethyl in Patients With Cardiovascular Disease and Hypertriglyceridemia (DEFAT Trial). <i>Circulation Journal</i> , 2019, 83, 1368-1376.	0.7	5
327	Triglycerides: Mendelian Randomization Studies Suggest Causal Role, but How to Treat in 2019?. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	0
328	Management of dyslipidaemias in the elderly populationâ€”A narrative review. <i>Maturitas</i> , 2019, 124, 93-99.	1.0	3
329	The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. <i>Endocrine Reviews</i> , 2019, 40, 537-557.	8.9	262
330	Elevated Serum Non-HDL (High-Density Lipoprotein) Cholesterol and Triglyceride Levels as Residual Risks for Myocardial Infarction Recurrence Under Statin Treatment. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 934-944.	1.1	25
331	Target of Triglycerides as Residual Risk for Cardiovascular Events in Patients With Coronary Artery Diseaseâ€”Post Hoc Analysis of the FMD-J Study A â€. <i>Circulation Journal</i> , 2019, 83, 1064-1071.	0.7	17
332	Triglycerides as Residual Risk for Atherosclerotic Cardiovascular Disease. <i>Circulation Journal</i> , 2019, 83, 969-970.	0.7	9
333	Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. <i>Current Diabetes Reports</i> , 2019, 19, 13.	1.7	32
334	Effect of Magnesium Supplementation on Lipid Profile: A Systematic Review of Randomized Clinical Trials. , 2019, , 277-286.		0
335	Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. <i>European Heart Journal</i> , 2020, 41, 86-94.	1.0	71
336	Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial. <i>Future Cardiology</i> , 2019, 15, 391-394.	0.5	10
337	Investigational drugs in development for hypertriglyceridemia: a coming-of-age story. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 1059-1079.	1.9	3
338	SPPARM alpha. <i>Current Opinion in Lipidology</i> , 2019, 30, 419-427.	1.2	11
339	<p>Elevated Triglycerides (â‰¥150 mg/dL) and High Triglycerides (200â€“499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients</p>. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 533-538.	1.0	13
340	Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statinâ€“controlled LDL cholesterol. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 366-371.	2.2	90

#	ARTICLE	IF	CITATIONS
341	Effects of carbohydrate-restricted diets on low-density lipoprotein cholesterol levels in overweight and obese adults: a systematic review and meta-analysis. <i>Nutrition Reviews</i> , 2019, 77, 161-180.	2.6	71
342	Riesgo cardiovascular residual de origen lipídico. Componentes y aspectos fisiopatológicos. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 75-88.	0.4	6
343	Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. <i>Journal of Clinical Lipidology</i> , 2019, 13, 100-108.	0.6	56
344	Management of Dyslipidemia. <i>Contemporary Cardiology</i> , 2019, , 39-69.	0.0	0
345	Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease. <i>Clinical Cardiology</i> , 2019, 42, 56-61.	0.7	25
346	Niacin and hyperlipidemia. , 2020, , 263-281.		3
347	Incorporating healthy dietary changes in addition to an increase in fruit and vegetable intake further improves the status of cardiovascular disease risk factors: A systematic review, meta-regression, and meta-analysis of randomized controlled trials. <i>Nutrition Reviews</i> , 2020, 78, 532-545.	2.6	19
348	Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 279-289.	2.2	33
349	Flexible modeling of ratio outcomes in clinical and epidemiological research. <i>Statistical Methods in Medical Research</i> , 2020, 29, 2250-2268.	0.7	3
350	Effects of nutrition education on cardio-metabolic outcomes: A randomised clinical trial. <i>Health Education Journal</i> , 2020, 79, 458-470.	0.6	0
351	Long-term prognostic utility of low-density lipoprotein (LDL) triglyceride in real-world patients with coronary artery disease and diabetes or prediabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 152.	2.7	9
352	Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100086.	1.3	10
353	When to lower triglycerides?. <i>Current Opinion in Lipidology</i> , 2020, 31, 238-245.	1.2	9
354	Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization) Tj ETQq1 1 0.784614 rgBT 10verlock 1		
355	Icosapent Ethyl: Niche Drug or for the Masses?. <i>Current Cardiology Reports</i> , 2020, 22, 104.	1.3	8
356	Targeting Inflammation After Myocardial Infarction. <i>Current Cardiology Reports</i> , 2020, 22, 110.	1.3	19
357	Prediction for cardiovascular diseases based on laboratory data: An analysis of random forest model. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23421.	0.9	26
358	Apolipoprotein B/A1 Ratio as a Diagnostic Alternative to Triglycerides and HDL-Cholesterol for the Prediction of Metabolic Syndrome among Hypertensives in Kazakhstan. <i>Diagnostics</i> , 2020, 10, 510.	1.3	8

#	ARTICLE	IF	CITATIONS
359	Prognostic impact of estimated remnant-like particle cholesterol in patients with differing glycometabolic status: an observational cohort study from China. <i>Lipids in Health and Disease</i> , 2020, 19, 179.	1.2	11
360	Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. <i>European Heart Journal</i> , 2020, 41, 3936-3945.	1.0	188
361	The role of intracoronary imaging in translational research. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1480-1507.	0.7	3
362	Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007-2014. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100087.	1.3	3
363	Prevalence of US Adults with Triglycerides $\geq 150$ mg/dl: NHANES 2007-2014. <i>Cardiology and Therapy</i> , 2020, 9, 207-213.	1.1	35
364	Apolipoprotein B/A-I Ratio Predicts Lesion Severity and Clinical Outcomes in Diabetic Patients With Acute Coronary Syndrome. <i>Circulation Journal</i> , 2020, 84, 1132-1139.	0.7	12
365	Insights into incretin-based therapies for treatment of diabetic dyslipidemia. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 34-53.	6.6	21
366	Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2020, 32, 120-125.	0.1	2
367	Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 361-379.	3.5	119
368	Association of high-density lipoprotein levels with baseline coronary plaque volumes by coronary CTA in the EVAPORATE trial. <i>Atherosclerosis</i> , 2020, 305, 34-41.	0.4	7
369	Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. <i>Current Atherosclerosis Reports</i> , 2020, 22, 25.	2.0	38
370	Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 175-180.	0.6	8
371	Triglycerides and residual risk. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 95-103.	1.2	42
372	Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients. <i>International Journal of Clinical Practice</i> , 2020, 74, e13508.	0.8	9
373	Omega-3 polyunsaturated fatty acids: anti-inflammatory and anti-hypertriglyceridemia mechanisms in cardiovascular disease. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 993-1003.	1.4	30
374	The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. <i>Postgraduate Medicine</i> , 2021, 133, 28-41.	0.9	10
375	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 49-56.	2.3	12
376	Atherogenic dyslipidaemia and cardiovascular events in patients with diabetes or pre-diabetes and stable coronary artery disease: a prospective, cohort study. <i>BMJ Open</i> , 2021, 11, e037340.	0.8	2

#	ARTICLE	IF	CITATIONS
377	TriglicÃ©ridos: Â¿son o no son un factor de riesgo cardiovascular?. , 2021, 32, 231-235.		1
378	Fish Oils. Stroke Revisited, 2021, , 111-123.	0.2	0
379	Biomarkers. , 2021, , 31-64.		0
380	Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 634-640.	1.1	10
381	Triglycerides and risk of atherosclerotic cardiovascular disease: An update. Archives of Cardiovascular Diseases, 2021, 114, 132-139.	0.7	39
382	Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study. Lipids in Health and Disease, 2021, 20, 17.	1.2	11
383	Lipid-lowering therapy: Guidelines to precision medicine. Clinica Chimica Acta, 2021, 514, 66-73.	0.5	7
384	Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment. Current Atherosclerosis Reports, 2021, 23, 27.	2.0	4
385	Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON. Cardiovascular Diabetology, 2021, 20, 94.	2.7	17
386	The role of icosapent ethyl in cardiovascular risk reduction. Current Opinion in Cardiology, 2021, 36, 661-671.	0.8	3
387	Coronary heart disease risk: Low-density lipoprotein and beyond. Trends in Cardiovascular Medicine, 2022, 32, 181-194.	2.3	56
388	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis, 2021, 325, 99-109.	0.4	83
389	The risk of carotid plaque instability in patients with metabolic syndrome is higher in women with hypertriglyceridemia. Cardiovascular Diabetology, 2021, 20, 98.	2.7	8
390	The use of blood biomarkers in precision medicine for the primary prevention of atherosclerotic cardiovascular disease: a review. Expert Review of Precision Medicine and Drug Development, 2021, 6, 247-258.	0.4	11
391	Triglycerides and Residual Atherosclerotic Risk. Journal of the American College of Cardiology, 2021, 77, 3031-3041.	1.2	82
393	Per-Particle Triglyceride-Rich Lipoproteins Imply Higher Myocardial Infarction Risk Than Low-Density Lipoproteins: Copenhagen General Population Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2063-2075.	1.1	21
394	Multi-trajectories of lipid indices with incident cardiovascular disease, heart failure, and all-cause mortality: 23Â½years follow-up of two US cohort studies. Journal of Translational Medicine, 2021, 19, 286.	1.8	9
395	Who would benefit most from postprandial lipid screening?. Clinical Nutrition, 2021, 40, 4762-4771.	2.3	6



#	ARTICLE	IF	CITATIONS
396	Predictive Value of the Triglyceride to High-Density Lipoprotein Cholesterol Ratio for All-Cause Mortality and Cardiovascular Death in Diabetic Patients With Coronary Artery Disease Treated With Statins. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 718604.	1.1	9
397	Association between ANGPTL3, 4, and 8 and lipid and glucose metabolism markers in patients with diabetes. <i>PLoS ONE</i> , 2021, 16, e0255147.	1.1	10
398	Real-world analyses of patients with elevated atherosclerotic cardiovascular disease risk from the Optum Research Database. <i>Future Cardiology</i> , 2021, 17, 743-755.	0.5	8
399	A Fishy Topic: VITAL, REDUCE-IT, STRENGTH, and Beyond: Putting Omega-3 Fatty Acids into Practice in 2021. <i>Current Cardiology Reports</i> , 2021, 23, 111.	1.3	13
400	2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia. <i>Journal of the American College of Cardiology</i> , 2021, 78, 960-993.	1.2	146
401	Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor $\delta$ Modulator (SPPARM $\delta$ ) in Japanese Patients with Renal Impairment and Dyslipidemia. <i>Internal Medicine</i> , 2021, 60, 2741-2748.	0.3	1
402	Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study. <i>Clinical Therapeutics</i> , 2021, 43, 1735-1747.	1.1	7
403	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	1.0	303
404	Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry. <i>International Journal of Cardiology</i> , 2021, 340, 96-104.	0.8	9
405	Lipoproteins in chronic kidney disease: from bench to bedside. <i>European Heart Journal</i> , 2021, 42, 2170-2185.	1.0	32
406	Lipid-Modifying Drugs: Pharmacology and Perspectives. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1177, 133-148.	0.8	6
407	The Contribution of Triglycerides and Triglyceride-Rich Lipoproteins to Atherosclerotic Cardiovascular Disease. , 2011, , 230-251.		1
408	Dislipidemia aterogénica 2019. Documento de consenso del Grupo de Dislipidemia Aterogénica de la Sociedad Española de Arteriosclerosis. <i>Clínica e Investigaci3n En Arteriosclerosis</i> , 2020, 32, 120-125.	0.4	5
409	Triglyceride and Cardiovascular Disease. <i>Journal of Lipid and Atherosclerosis</i> , 2013, 2, 1.	1.1	8
410	A Common CNR1 (Cannabinoid Receptor 1) Haplotype Attenuates the Decrease in HDL Cholesterol That Typically Accompanies Weight Gain. <i>PLoS ONE</i> , 2010, 5, e15779.	1.1	12
411	Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. <i>PLoS ONE</i> , 2015, 10, e0125512.	1.1	30
412	Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPAR $\delta$ signaling pathway. <i>PLoS ONE</i> , 2017, 12, e0184949.	1.1	15
413	Beneficial Effects of Fennel ( <i>Foeniculum Vulgare</i> ) in Treating Obesity in Rats. <i>Journal of Obesity Management</i> , 2016, 1, 16-33.	0.4	6

#	ARTICLE	IF	CITATIONS
414	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. <i>European Cardiology Review</i> , 2020, 15, 1-9.	0.7	38
415	Association between atherogenic dyslipidemia and fourier's gangrene. <i>Revista Da Associação Médica Brasileira</i> , 2020, 66, 479-484.	0.3	2
416	Saroglitazar: A New Drug to Treat Diabetic Hypertriglyceridemia. <i>Heart Research - Open Journal</i> , 2017, 4, 12-17.	0.2	1
417	Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes: Recent Clinical Trials. <i>Review of Diabetic Studies</i> , 2013, 10, 191-203.	0.5	11
418	Pharmacological Effects of Niacin on Acute Hyperlipemia. <i>Current Medicinal Chemistry</i> , 2016, 23, 2826-2835.	1.2	12
419	Clinical Significance of On-Treatment Triglyceride Level in Patients Treated by Percutaneous Coronary Intervention for Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Korean Journal of Internal Medicine</i> , 2009, 24, 330.	0.7	1
420	Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 78.	1.8	7
421	Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 213.	1.8	43
422	Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population. <i>Indian Journal of Endocrinology and Metabolism</i> , 2016, 20, 67.	0.2	4
423	Research progress of hypertriglyceridemia and coronary heart disease. <i>Heart and Mind (Mumbai)</i> , 2020, 11, 1-5.	0.2	5
424	Association between dairy product intake and hypertriglyceridemia in Korean adults. <i>Nutrition Research and Practice</i> , 2020, 14, 152.	0.7	11
425	Maintaining Cardiovascular Health in Patients With Mixed Dyslipidemia Optimizing the Management of Hypertriglyceridemia and Non-HDL Cholesterol. <i>Journal of Managed Care Pharmacy</i> , 2009, 15, 1-22.	2.2	0
426	Dyslipidemia and Atherosclerosis. , 2009, , .		0
427	Risk Assessment for Complications of Diabetes Mellitus. , 2009, , 195-241.		0
428	Effects of <i>Sasa coreana</i> Nakai on the Lipid Compositions of Serum in High Cholesterol Diet Rats. <i>Journal of Life Science</i> , 2009, 19, 1145-1151.	0.2	8
429	Dyslipidemia: Pathogenesis and Management. , 2010, , 435-456.		0
430	Atherosclerosis. , 2010, , 287-491.		0
431	Ezetimibe in the Treatment of Patients with Metabolic Diseases. <i>European Endocrinology</i> , 2010, 9, 55.	0.8	0



#	ARTICLE	IF	CITATIONS
432	Prise en charge du diab�tologique apr�s infarctus du myocarde. , 2010, , 346-351.		0
433	Residual Risk Reduction Initiative: v�zva ke sn�34en�rezidu�ln�ho vaskul�rn�ho rizika u pacient� s dyslipidemi�. Cor Et Vasa, 2010, 52, 212-228.	0.1	0
434	Cardiovascular Epidemiology and Characterization of Atherosclerotic Disease Risk Factors. , 2011, , 3-24.		0
435	Management of Dyslipidemia. , 2011, , 59-89.		0
436	Evaluation on Management of Dyslipidemia in Diabetic Patients. Journal of Korean Society of Health-System Pharmacists, 2010, 27, 417-426.	0.1	0
437	Persistent dyslipidemia in statin-treated patients. focus on comprehensive lipid management survey in Swiss patients. Swiss Medical Weekly, 2011, 141, w13200.	0.8	5
438	A closer look at lipid management following an acute coronary syndrome. , 2011, , 45-54.		0
439	Association between change in HDL-C and vascular events in patients treated with statins: Report from the UK general practice research database. World Journal of Cardiovascular Diseases, 2012, 02, 64-73.	0.0	0
440	Residual Risk and Biology of the Disease: Implications for Plaque Imaging. Contemporary Cardiology, 2014, , 1-21.	0.0	1
441	Comparison of Changes in Body Weight and Serum Lipid Profile after Roux-en-Y Gastric Bypass between Non-obese Patients and Obese Patients. The Korean Journal of Obesity, 2014, 23, 164.	0.2	0
443	Rapid progression of nonculprit coronary lesions six weeks after successful primary PCI in culprit artery: a case report. Journal of Biomedical Research, 2014, 28, 146.	0.7	2
445	Statins and Fibrates: Should They Be Recommended?. , 2015, , 11-23.		1
446	Optimizing the Effect of �-3 Fatty Acids on the Lipid Profile in Metabolic Syndrome Patients. European Journal of Preventive Medicine, 2015, 3, 180.	0.1	0
447	Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering. Journal of the Japanese Coronary Association, 2016, 22, 217-227.	0.0	0
448	Prise en charge du diab�tologique apr�s infarctus du myocarde. , 2019, , 469-474.		0
449	Control del perfil lip�dico global. Cl�nica E Investigaci�n En Arteriosclerosis, 2019, 31, 34-41.	0.4	1
450	Possibilities of Pulse Wave Contour Analysis in Diagnostics of Early Vascular Aging. Rational Pharmacotherapy in Cardiology, 2020, 16, 356-362.	0.3	2
451	Role of omega-3 polyunsaturated fatty acids in cardiovascular risk management. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2589.	0.4	2

#	ARTICLE	IF	CITATIONS
452	Management of Hypertriglyceridemia (Including Fibrates and n-3 Fatty Acids). <i>Contemporary Cardiology</i> , 2021, , 295-306.	0.0	1
453	Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk. <i>Contemporary Cardiology</i> , 2021, , 139-158.	0.0	2
454	Apolipoprotein C-II and C-III preferably transfer to both high-density lipoprotein (HDL) and the larger HDL from very low-density lipoprotein (VLDL). <i>Biological Chemistry</i> , 2021, 402, 439-449.	1.2	6
455	Peculiarities of Clinical Presentations and Long-Term Complications in Patients with Coronary Artery Disease and Metabolic Syndrome, depending on their Serum Triglyceride Levels. <i>Ukrainian Journal of Medicine in Biology and Sports</i> , 2020, 5, 125-134.	0.0	0
456	The Clinical Values of Afamin, Triglyceride and PLR in Predicting Risk of Gestational Diabetes During Early Pregnancy. <i>Frontiers in Endocrinology</i> , 2021, 12, 723650.	1.5	10
458	An analysis of the risk factors for premature coronary artery disease in young and middle-age Chinese patients with hypertension. <i>Experimental and Clinical Cardiology</i> , 2013, 18, 89-92.	1.3	7
459	Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. <i>Canadian Family Physician</i> , 2013, 59, 1169-80.	0.1	38
460	Non-High-Density Lipoproteins Cholesterol and Cardio-Metabolic Risk. <i>Medicina</i> , 2015, 10, 33-8.	0.4	1
461	The Microvascular and Macrovascular Benefits of Fibrates in Diabetes and the Metabolic Syndrome: A review. <i>Missouri Medicine</i> , 2017, 114, 464-471.	0.3	6
462	Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. <i>Acta Cardiologica Sinica</i> , 2018, 34, 371-378.	0.1	12
464	Normal-weight central obesity: Unique hazard of the toxic waist. <i>Canadian Family Physician</i> , 2019, 65, 399-408.	0.1	21
465	Risk Factors in Patients with Non-ST Segment Elevation Myocardial Infarction. <i>Materia Socio-medica</i> , 2020, 32, 224-226.	0.3	0
466	Contribution of Hypertriglyceridemia to Ischemic Cardiovascular Disease in Korean Women: A Nationwide Population-based Study. <i>Journal of Clinical Lipidology</i> , 2021, , .	0.6	2
467	Cardiovascular disease risk reduction with wolfberry consumption: a systematic review and meta-analysis of randomized controlled trials. <i>European Journal of Nutrition</i> , 2022, 61, 1177-1186.	1.8	4
468	Impact of triglyceride levels on plaque characteristics in patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2022, 348, 134-139.	0.8	4
469	Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 42.	0.8	1
470	Essential Polyunsaturated Fatty Acids in Blood from Patients with and without Catheter-Proven Coronary Artery Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 766.	1.8	6
471	Triglyceride/low-density-lipoprotein cholesterol ratio is the most valuable predictor for increased small, dense LDL in type 2 diabetes patients. <i>Lipids in Health and Disease</i> , 2022, 21, 4.	1.2	14

#	ARTICLE	IF	CITATIONS
472	Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design. <i>Clinical Cardiology</i> , 2022, , .	0.7	3
474	Efficacy and Safety of Da-Chai-Hu-Tang in Lipid Profiles in High-Risk, Statin-Treated Patients with Residual HyperTG: A 12-Week, Randomized, Active-Control, Open Clinical Study. <i>Life</i> , 2022, 12, 408.	1.1	3
475	Contemporary Management of Dyslipidemia. <i>Drugs</i> , 2022, 82, 559-576.	4.9	14
476	Prognostic Role of Hypertriglyceridemia in Patients With Stroke of Atherothrombotic Origin. <i>Neurology</i> , 2022, 98, .	1.5	7
477	Apolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analyses. <i>Journal of Lipid Research</i> , 2022, , 100193.	2.0	4
478	Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. , 2022, 237, 108172.		18
479	The Achievement of Non-high-density Lipoprotein Cholesterol Target in Patients with Very High Atherosclerotic Cardiovascular Disease Risk Stratified by Triglyceride Levels Despite Statin-controlled Low-density Lipoprotein Cholesterol. <i>Oman Medical Journal</i> , 2022, 37, e367-e367.	0.3	1
481	Arterial Stiffness Determinants for Primary Cardiovascular Prevention among Healthy Participants. <i>Journal of Clinical Medicine</i> , 2022, 11, 2512.	1.0	12
482	Lipid-modifying and antiatherosclerotic drugs. , 2013, , 398-435.		3
484	New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention. <i>Current Cardiovascular Risk Reports</i> , 2022, 16, 69-78.	0.8	5
486	Management of Mild-to-Moderate Hypertriglyceridemia. <i>Endocrine Practice</i> , 2022, 28, 1187-1195.	1.1	2
487	Pharmacokinetics of Icosapent Ethyl: An Open-Label, Multiple Oral Dose, Parallel Design Study in Healthy Chinese Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2023, 12, 6-13.	0.8	0
489	Effect of Novel Stratified Lipid Risk by "LDL-Window" and Flow-Mediated Dilation on the Prognosis of Coronary Artery Disease Using the FMD-J Study A Data. <i>Circulation Journal</i> , 2022, 86, 1444-1454.	0.7	4
490	Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention. <i>Current Atherosclerosis Reports</i> , 2022, 24, 767-778.	2.0	7
491	Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. <i>Circulation</i> , 2022, 146, 657-672.	1.6	32
492	Emerging Markers for Cardiovascular Risk Assessment. <i>Advances in Clinical Medicine</i> , 2022, 12, 9155-9161.	0.0	0
493	"Use of lipid-lowering therapy: the guidelines, the drugs or the patient?"™. <i>European Heart Journal Supplements</i> , 2022, 24, I29-I33.	0.0	1
494	Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society]. <i>Endocrinología y Nutrición (English Ed.)</i> , 2023, 70, 51-62.	0.1	0

#	ARTICLE	IF	CITATIONS
495	A Multi-Center, Prospective Observational Study to Investigate the Safety, Compliance, and Efficacy of Omethyl QTlet Soft Capsule. <i>Journal of Clinical Medicine</i> , 2022, 11, 6949.	1.0	0
496	Management of diabetic dyslipidemia in Indians: Expert consensus statement from the Lipid Association of India. <i>Journal of Clinical Lipidology</i> , 2023, 17, e1-e14.	0.6	5
497	Dysregulation of Angiopoietin-like-4 Associated with Hyperlipidemia-induced Renal Injury by AMPK/ACC Pathway. <i>Current Pharmaceutical Design</i> , 2023, 29, 300-309.	0.9	0
498	Plant-Based Diets and Lipid, Lipoprotein, and Inflammatory Biomarkers of Cardiovascular Disease: A Review of Observational and Interventional Studies. <i>Nutrients</i> , 2022, 14, 5371.	1.7	8
499	Management of Patients with Type V Hyperlipoproteinemia: An Uncommon Phenotype of Dyslipidemia with Chylomicronemia and Severe Hypertriglyceridemia. <i>Journal of Personalized Medicine</i> , 2023, 13, 68.	1.1	0
501	What is really new in triglyceride guidelines?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2023, 30, 73-80.	1.2	0
502	VLDL receptor gene therapy for reducing atherogenic lipoproteins. <i>Molecular Metabolism</i> , 2023, 69, 101685.	3.0	5
503	Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2023, 33, 1444-1452.	1.1	1
504	Complexity of triglyceride-rich lipoprotein remnant cholesterol with atherosclerotic cardiovascular disease risk. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 1139-1141.	0.8	4
505	Study on VLDLR Gene Therapy for Reducing Atherogenic Lipoprotein. <i>Advances in Clinical Medicine</i> , 2023, 13, 3424-3430.	0.0	0
506	Lipid Order of Membranes Isolated from Erythrocytes of Patients with Coronary Artery Disease: Correlation with Biochemical Parameters. <i>Lecture Notes in Networks and Systems</i> , 2023, , 134-146.	0.5	0
509	Triglycerides, Triglyceride-Rich Lipoproteins, and High-Density Lipoprotein in Coronary Heart Disease Risk Assessment. , 2024, , 32-41.e2.		0
512	Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes Mellitus Type 2. <i>Contemporary Diabetes</i> , 2023, , 637-679.	0.0	0
513	Omega-3 Fatty Acids. , 2024, , 169-183.e3.		0
514	Special Patient Populations. , 2024, , 298-306.e2.		0
515	Special Patient Populations. , 2024, , 345-357.e3.		0
520	Wearable sensor platform in real time monitoring and early warning of metabolic disorders in human health. <i>Analyst, The</i> , 0, , .	1.7	0
528	Overview of Inpatient Management of Hypertriglyceridemia Associated Acute Pancreatitis in Patients with Diabetes Mellitus. <i>Contemporary Endocrinology</i> , 2023, , 193-206.	0.3	0

#	ARTICLE	IF	CITATIONS
530	A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids. Cardiovascular Drugs and Therapy, 0, , .	1.3	0